Thursday, July 12, 2012
Novo Nordisk A/S has partnered with JDRF to help populate
the pharma's newly opened Type 1 Diabetes R&D Center in Seattle with early
stage projects. The center will run side-by-side comparisons of technologies
being developed through the foundation's sponsored projects as well as other
opportunities the partners identify. A joint committee will select the most
promising for further development by the pharma.
A space with
Lou, K.-J. SciBX 5(27);
Published online July 12, 2012
AND INSTITUTIONS MENTIONED
JDRF, New York, N.Y.
La Jolla Institute for Allergy & Immunology,
La Jolla, Calif.
Novo Nordisk A/S (CSE:NVO;
NYSE:NVO), Bagsvaerd, Denmark